The complement model disease paroxysmal nocturnal hemoglobinuria
European Journal of Immunology · 2024
DOI: 10.1002/eji.202350817 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Immunology, 2024. Verfasst von Christoph Q Schmidt und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Experimental and Clinical Pharmacology, Toxicology and Pharmacology of Natural Products, University of Ulm Medical Centre, Ulm, Germany. Hauptthemen laut MEDLINE: Hemoglobinuria, Paroxysmal, Complement Activation, Hemolysis, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
We describe initial, current, and future aspects of complement activation and inhibition in the rare hematological disease paroxysmal nocturnal hemoglobinuria (PNH). PNH is a rare but severe hematological disorder characterized by complement‐mediated intravascular hemolysis resulting in anemia and severe thrombosis. Insights into the complement‐mediated pathophysiology ultimately led to regulatory approval of the first‐in‐class complement inhibitor, eculizumab, in 2007. This anti‐complement C5 therapy resulted in the stabilization of many hematologic parameters and dramatically reduced the often fatal, coagulant‐resistant thrombotic events. Despite the remarkable clinical success, a substantial proportion of PNH patients experience suboptimal clinical responses during anti‐C5 therapy. We describe the identification and mechanistic dissection of four unexpected processes responsible for such suboptimal clinical responses: (1) pharmacokinetic and (2) pharmacodynamic intravascular breakthrough hemolysis, (3) continuing low‐level residual intravascular hemolysis, and (4) extravascular hemolysis. Novel complement therapeutics mainly targeting different complement proteins proximal in the cascade attempt to address these remaining problems. With five approved complement inhibitors in the clinic and many more being evaluated in clinical trials, PNH remains one of the complement diseases with the highest intensity of clinical research. Mechanistically unexpected breakthrough events occur not only with C5 inhibitors but also with proximal pathway inhibitors, which require further mechanistic elaboration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Experimental and Clinical Pharmacology, Toxicology and Pharmacology of Natural Products, University of Ulm Medical Centre, Ulm, Germany.
- Institute of Transfusion Medicine, University of Ulm, Ulm, Germany.
- Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden-Württemberg-Hessen and University Hospital of Ulm, Ulm, Germany.
Förderung
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Schmidt, C. Q., Höchsmann, B., & Schrezenmeier, H. (2024). The complement model disease paroxysmal nocturnal hemoglobinuria. European Journal of Immunology. https://doi.org/10.1002/eji.202350817
Vancouver
Schmidt CQ, Höchsmann B, Schrezenmeier H. The complement model disease paroxysmal nocturnal hemoglobinuria. European Journal of Immunology. 2024. doi:10.1002/eji.202350817
BibTeX
@article{Schmidt2024,
author = {Schmidt, Christoph Q and Höchsmann, Britta and Schrezenmeier, Hubert},
title = {The complement model disease paroxysmal nocturnal hemoglobinuria},
journal = {European Journal of Immunology},
year = {2024},
doi = {10.1002/eji.202350817}
}
EUVIMED